

REMARKS

The pending claims have been rewritten as claims 34-50 to conform with US practice. Claims 34-50 are supported throughout the specification, including the original claims. For example, the % identities recited in claims 35-40 are supported by page 7, lines 16-20 of the specification.

The Office Action requested that Applicants elect a species of a hybrid enzyme comprising a carbohydrate-binding module. In response to this requirement, Applicants elect with traverse a hybrid enzyme comprising an *Aspergillus kawachi* alpha-amylase carbohydrate-binding module. New claims 34-50 read thereon.

The basis for traverse is that there would not be a serious burden on the examiner if restriction were not required.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: April 6, 2009

/Elias Lambiris, Reg. # 33728/
Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097